Latest News

June 18, 2014
The Ras protein is one of the most common and deadly drivers of cancer, yet it has eluded any drug therapies for decades. Scientists are getting close to changing that.
June 03, 2014
The New York Times Health for Tomorrow conference, held at UCSF, featured experts from the University of California and across the country, addressing the changing landscape of health care.
April 17, 2014
Nobel Prize winner Stanley Prusiner is closing in on better treatments for Alzheimer's, Parkinson's and other brain diseases, and an unlikely new partnership will get him there faster.
March 05, 2014
UCSF is changing the way you think about your neighborhood drugstore by putting the pharmacist front and center – not just in the store, but also on your health care team.
October 02, 2013
Brian Alldredge, associate dean for the UCSF School of Pharmacy for the past 12 years and a member of the faculty for 28 years, has been named Vice Provost for Academic Affairs.
July 05, 2013
The nation's premier pharmacy school capped its academic year by welcoming a new dean and celebrating a stellar class of graduates at its commencement ceremony on May 24.
June 18, 2013
Lisa Kroon, PharmD, has been named the new chair of the Department of Clinical Pharmacy within the UCSF School of Pharmacy, effective July 1. Kroon has served as interim chair of the department since July 2012, when the previous chair, B. Joseph Guglielmo, PharmD, became interim dean and later dean of the School of Pharmacy.
May 09, 2013
Two UCSF scientists — brain researcher Michael Brainard, PhD, and cell biologist Dyche Mullins, PhD — have been selected to be Howard Hughes Medical Institute investigators.
March 21, 2013
UCSF has named a highly accomplished pharmacist and clinical scientist, B. Joseph Guglielmo, PharmD, a 34-year member of the UCSF faculty, to lead the nation’s premier School of Pharmacy.
December 06, 2012
The rate of cancer survival is expected to keep climbing in coming years largely thanks to research discoveries that are translating into new cancer drugs, which currently account for roughly 30 percent of the pharmaceutical dollar, the chief scientific officer at Bristol-Myers Squib recently said at a showcase event for the UCSF Helen Diller Family Comprehensive Cancer Center.

Pages